Literature DB >> 28554066

The neural basis of deficient response inhibition in children with neurofibromatosis type 1: Evidence from a functional MRI study.

Natalie A Pride1, Mayuresh S Korgaonkar2, Kathryn N North3, Belinda Barton4, Jonathan M Payne3.   

Abstract

Impaired response inhibition is a predominant feature of several neuropsychiatric disorders; in general the underlying aetiology of these disorders and associated impairments is unknown. The common occurrence of impaired response inhibition in a single gene disorder such as neurofibromatosis type 1 (NF1), provides a valuable opportunity to explore its mechanistic basis through the study of gene-brain-behaviour interactions. We used functional brain imaging with a Go/No-Go task to examine the neural substrates of response inhibition in children with NF1 and age and gender matched typically developing subjects. Children with NF1 were found to have abnormal activation patterns in several cortical regions, with significantly reduced activation in the inferior occipital gyrus (IOG), the fusiform gyrus/posterior cerebellum (FG/PC), the pre-supplementary motor area (pre-SMA) and the inferior frontal gyrus (IFG). Importantly, activation in the right IFG was associated with faster task reaction times and impairment in sustained attention in subjects with NF1. Our study supports the hypothesis that a network of regions typically associated with response inhibition is dysfunctional in children with NF1 and suggests this dysfunction is linked to cognitive impairment in this disorder. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Functional magnetic resonance imaging; Neurofibromatosis 1

Mesh:

Year:  2017        PMID: 28554066     DOI: 10.1016/j.cortex.2017.04.022

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  7 in total

1.  Social Function and Autism Spectrum Disorder in Children and Adults with Neurofibromatosis Type 1: a Systematic Review and Meta-Analysis.

Authors:  Anita K Chisholm; Vicki A Anderson; Natalie A Pride; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  Neuropsychol Rev       Date:  2018-08-11       Impact factor: 7.444

2.  Discriminating between neurofibromatosis-1 and typically developing children by means of multimodal MRI and multivariate analyses.

Authors:  Federico Nemmi; Fabien Cignetti; Christine Assaiante; Stephanie Maziero; Fredrique Audic; Patrice Péran; Yves Chaix
Journal:  Hum Brain Mapp       Date:  2019-05-11       Impact factor: 5.038

3.  From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.

Authors:  Rosalie E Ferner; Annette Bakker; Ype Elgersma; D Gareth R Evans; Marco Giovannini; Eric Legius; Alison Lloyd; Ludwine M Messiaen; Scott Plotkin; Karlyne M Reilly; Aaron Schindeler; Miriam J Smith; Nicole J Ullrich; Brigitte Widemann; Larry S Sherman
Journal:  Am J Med Genet A       Date:  2019-03-25       Impact factor: 2.802

Review 4.  An executive functioning perspective in neurofibromatosis type 1: from ADHD and autism spectrum disorder to research domains.

Authors:  Taylor F Smith; Jessica A Kaczorowski; Maria T Acosta
Journal:  Childs Nerv Syst       Date:  2020-07-03       Impact factor: 1.475

5.  Effects of methylphenidate on cognition and behaviour in children with neurofibromatosis type 1: a study protocol for a randomised placebo-controlled crossover trial.

Authors:  Natalie A Pride; Belinda Barton; Paul Hutchins; David R Coghill; Mayuresh S Korgaonkar; Stephen J C Hearps; Melissa Rouel; Stephanie Malarbi; Kathryn N North; Jonathan M Payne
Journal:  BMJ Open       Date:  2018-08-30       Impact factor: 2.692

6.  Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model.

Authors:  J L Lukkes; H P Drozd; S D Fitz; A I Molosh; D W Clapp; A Shekhar
Journal:  J Neurodev Disord       Date:  2020-01-15       Impact factor: 4.025

7.  Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.

Authors:  Jonathan M Payne; Stephen J C Hearps; Karin S Walsh; Iris Paltin; Belinda Barton; Nicole J Ullrich; Kristina M Haebich; David Coghill; Gerard A Gioia; Alan Cantor; Gary Cutter; James H Tonsgard; David Viskochil; Celiane Rey-Casserly; Elizabeth K Schorry; Joseph D Ackerson; Laura Klesse; Michael J Fisher; David H Gutmann; Tena Rosser; Roger J Packer; Bruce Korf; Maria T Acosta; Kathryn N North
Journal:  Ann Clin Transl Neurol       Date:  2019-12-03       Impact factor: 4.511

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.